Literature DB >> 7530627

Current and potential treatment of tuberculosis.

S Houston1, A Fanning.   

Abstract

A recent resurgence of interest in tuberculosis as a global health problem has accompanied the resurgence of tuberculosis in both industrialised and developing countries. It has also been demonstrated recently that tuberculosis treatment and control is one of the most cost effective of all medical interventions. The human immunodeficiency virus (HIV) epidemic and increasing resistance to antituberculous drugs complicate our response to the problem of tuberculosis. Chemotherapy with currently available agents is highly effective, not only in pulmonary tuberculosis in adults, but also in extrapulmonary disease, and in disease in children and even patients with concomitant HIV infection. Short course chemotherapy and intermittent therapy are as effective as older regimens. Measures, including directly observed therapy, to maximise compliance with therapy, are of utmost importance. An efficient programme which assures compliance with effective antituberculosis chemotherapy should be a priority for health spending even in those countries with fewest resources.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7530627     DOI: 10.2165/00003495-199448050-00004

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  146 in total

Review 1.  Tuberculosis and pregnancy.

Authors:  M A Hamadeh; J Glassroth
Journal:  Chest       Date:  1992-04       Impact factor: 9.410

Review 2.  Mycobacteria and the new quinolones.

Authors:  D C Leysen; A Haemers; S R Pattyn
Journal:  Antimicrob Agents Chemother       Date:  1989-01       Impact factor: 5.191

3.  Results at 5 years of a controlled comparison of a 6-month and a standard 18-month regimen of chemotherapy for pulmonary tuberculosis.

Authors: 
Journal:  Am Rev Respir Dis       Date:  1977-07

4.  The surgery for pulmonary tuberculosis.

Authors:  E A Gaensler
Journal:  Am Rev Respir Dis       Date:  1982-03

5.  Six-months versus nine-months chemotherapy for tuberculosis of lymph nodes: preliminary results. British Thoracic Society Research Committee.

Authors: 
Journal:  Respir Med       Date:  1992-01       Impact factor: 3.415

6.  Tuberculous meningitis. Short course of chemotherapy.

Authors:  F Alarcón; L Escalante; Y Pérez; H Banda; G Chacón; G Dueñas
Journal:  Arch Neurol       Date:  1990-12

7.  Risk for developing tuberculosis among anergic patients infected with HIV.

Authors:  S Moreno; J Baraia-Etxaburu; E Bouza; F Parras; M Pérez-Tascón; P Miralles; T Vicente; J C Alberdi; J Cosín; D López-Gay
Journal:  Ann Intern Med       Date:  1993-08-01       Impact factor: 25.391

8.  Cohort study of human immunodeficiency virus infection in patients with tuberculosis in Nairobi, Kenya. Analysis of early (6-month) mortality.

Authors:  P Nunn; R Brindle; L Carpenter; J Odhiambo; K Wasunna; R Newnham; W Githui; S Gathua; M Omwega; K McAdam
Journal:  Am Rev Respir Dis       Date:  1992-10

9.  Estimates of future global tuberculosis morbidity and mortality.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1993-12-17       Impact factor: 17.586

Review 10.  Treatment of tuberculosis during pregnancy.

Authors:  D E Snider; P M Layde; M W Johnson; M A Lyle
Journal:  Am Rev Respir Dis       Date:  1980-07
View more
  7 in total

1.  Exposure of mycobacteria to cell wall-inhibitory drugs decreases production of arabinoglycerolipid related to Mycolyl-arabinogalactan-peptidoglycan metabolism.

Authors:  Yoann Rombouts; Belinda Brust; Anil K Ojha; Emmanuel Maes; Bernadette Coddeville; Elisabeth Elass-Rochard; Laurent Kremer; Yann Guerardel
Journal:  J Biol Chem       Date:  2012-02-07       Impact factor: 5.157

2.  Thiosemicarbazole (thiacetazone-like) compound with activity against Mycobacterium avium in mice.

Authors:  Luiz E Bermudez; Robert Reynolds; Peter Kolonoski; Pricilla Aralar; Clark B Inderlied; Lowell S Young
Journal:  Antimicrob Agents Chemother       Date:  2003-08       Impact factor: 5.191

Review 3.  Avoidance and management of adverse reactions to antituberculosis drugs.

Authors:  A M Patel; J McKeon
Journal:  Drug Saf       Date:  1995-01       Impact factor: 5.606

4.  EthA, a common activator of thiocarbamide-containing drugs acting on different mycobacterial targets.

Authors:  Lynn G Dover; Anuradha Alahari; Paul Gratraud; Jessica M Gomes; Veemal Bhowruth; Robert C Reynolds; Gurdyal S Besra; Laurent Kremer
Journal:  Antimicrob Agents Chemother       Date:  2007-01-12       Impact factor: 5.191

5.  Oral pyridoxine can substitute for intravenous pyridoxine in managing patients with severe poisoning with isoniazid and rifampicin fixed dose combination tablets: a case report.

Authors:  M D S A Dilrukshi; C A P Ratnayake; C A Gnanathasan
Journal:  BMC Res Notes       Date:  2017-08-08

6.  Thiacetazone, an antitubercular drug that inhibits cyclopropanation of cell wall mycolic acids in mycobacteria.

Authors:  Anuradha Alahari; Xavier Trivelli; Yann Guérardel; Lynn G Dover; Gurdyal S Besra; James C Sacchettini; Robert C Reynolds; Geoffrey D Coxon; Laurent Kremer
Journal:  PLoS One       Date:  2007-12-19       Impact factor: 3.240

7.  Silymarin protects liver against toxic effects of anti-tuberculosis drugs in experimental animals.

Authors:  Sude Eminzade; Fikriye Uraz; Fikret V Izzettin
Journal:  Nutr Metab (Lond)       Date:  2008-07-05       Impact factor: 4.169

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.